Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21600900 | 0.93 | FGFR1 (0.48) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600901 | 0.91 | FGFR1 (0.54) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600906 | 0.91 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600917 | 0.88 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600892 | 0.87 | FGFR1 (0.47) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600947 | 0.86 | FGFR4 (0.48) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600955 | 0.86 | JAK3 (0.47) | FGFR1FGFR4FGFR2FGFR3JAK3 | |
| SCHEMBL21600961 | 0.85 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21600899 | 0.85 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL21601052 | 0.84 | FGFR4 (0.54) | FGFR1FGFR4FGFR2FGFR3MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019242689-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-12-26 | — | — | WO | disclosed |